One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Capricor Therapeutics just hit that mark, with a jump from 80 to 88 Monday.
Looking For The Best Stocks To Buy And Watch? Start Here
This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against that of all other stocks.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Capricor Therapeutics has risen more than 5% past a 5.48 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% EPS growth in its most recent report. Revenue gains came in at -100%.
Capricor Therapeutics earns the No. 231 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
